• 1. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 2. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 3. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 4. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 5. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Keto acids and derivatives Beta-keto acids and derivatives

Recent Advances in the Study of (E)-Ethyl 2-((dimethylamino)methylene)-3-oxobutanoate (CAS: 203186-58-7) and Its Applications in Chemical Biology and Pharmaceutical Research

(E)-Ethyl 2-((dimethylamino)methylene)-3-oxobutanoate (CAS: 203186-58-7) is a key intermediate in the synthesis of various heterocyclic compounds, which are of significant interest in medicinal chemistry and drug discovery. Recent studies have highlighted its utility in the development of novel bioactive molecules, particularly in the fields of oncology, infectious diseases, and neurological disorders. This research briefing aims to summarize the latest findings related to this compound, focusing on its synthetic applications, biological activities, and potential therapeutic implications.

One of the most notable advancements in the use of (E)-Ethyl 2-((dimethylamino)methylene)-3-oxobutanoate is its role in the synthesis of pyrazole and pyrimidine derivatives. These heterocycles are known for their diverse pharmacological properties, including anti-inflammatory, antimicrobial, and anticancer activities. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives synthesized using this compound exhibited potent inhibitory effects against several cancer cell lines, with IC50 values in the low micromolar range. The study also identified specific structural modifications that enhance binding affinity to target proteins, such as kinases and histone deacetylases.

In addition to its applications in oncology, (E)-Ethyl 2-((dimethylamino)methylene)-3-oxobutanoate has been explored as a building block for antiviral agents. Recent research has shown that its incorporation into nucleoside analogs can improve their pharmacokinetic properties and reduce off-target effects. For instance, a 2022 study in Antiviral Research reported the successful synthesis of a series of ribavirin analogs using this compound, which displayed enhanced activity against RNA viruses, including SARS-CoV-2 and influenza. These findings underscore the potential of this intermediate in addressing emerging viral threats.

Another area of interest is the compound's role in neuropharmacology. A 2023 preprint on bioRxiv described the use of (E)-Ethyl 2-((dimethylamino)methylene)-3-oxobutanoate in the development of small-molecule modulators of glutamate receptors. These modulators showed promise in preclinical models of neurodegenerative diseases, such as Alzheimer's and Parkinson's, by selectively targeting NMDA and AMPA receptors. The study also highlighted the compound's favorable safety profile and bioavailability, making it a viable candidate for further drug development.

From a synthetic chemistry perspective, recent advancements have focused on optimizing the yield and purity of (E)-Ethyl 2-((dimethylamino)methylene)-3-oxobutanoate. A 2023 paper in Organic Process Research & Development detailed a scalable, green chemistry approach using catalytic amounts of Lewis acids, which reduced waste and improved efficiency. This method is particularly relevant for industrial-scale production, where cost-effectiveness and environmental impact are critical considerations.

In conclusion, (E)-Ethyl 2-((dimethylamino)methylene)-3-oxobutanoate (CAS: 203186-58-7) continues to be a versatile and valuable intermediate in chemical biology and pharmaceutical research. Its applications span multiple therapeutic areas, and ongoing studies are likely to uncover additional uses for this compound. Future research should focus on elucidating its mechanism of action in various biological systems and exploring its potential in combination therapies. The compound's adaptability and efficacy make it a promising candidate for the next generation of bioactive molecules.

• 89193-23-7(ethyl 2-(dimethylamino)methylidene-3-oxopentanoate)
• 112476-73-0(3-[(dimethylamino)methylene]-2,4(3H,5H)-Furandione)
• 10177-34-1(Ethyl 4-hydroxynicotinate)
• 51145-57-4(ethyl 2-(dimethylaminomethylene)-3-oxo-butanoate)
• 57905-31-4(Ethyl 4-hydroxynicotinate)
• 51559-52-5(methyl 2-(dimethylamino)methylidene-3-oxobutanoate)
• 100643-08-1(Butanoic acid, 2-(aminomethylene)-3-oxo-, ethyl ester, (Z)-)
• 74632-03-4(Diethyl 4-oxo-1,4-dihydro-3,5-pyridinedicarboxylate)
• 116344-09-3(Ethyl 2-(Dimethylamino)methylidene-4-methyl-3-oxopentanoate)
• 93552-74-0(Butanoic acid,2-[(dimethylamino)methylene]-3-oxo-, 1,1-dimethylethyl ester)